Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
Date:2/9/2011

e escalation safety study in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

"We are very excited about the anti-GITR program, notably the unique and multifaceted mechanism of action and its promising safety profile," said Tony deFougerolles, Tolerx Chief Scientific Officer. "The preclinical data indicate that TRX518 has tremendous potential for enhancing anti-tumor responses, regardless of tumor type, and for also improving the effectiveness of other cancer therapies including chemotherapeutics and cancer vaccines."

About TRX518

TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses of TRX518 in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines. 

About Tolerx

Tolerx, Inc., a world leader in immunology for novel drug development, has a portfolio of innovative, first-in-class drug candidates to treat autoimmune diseases, d
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... 31, 2014 Astellas has appointed ... and employee communications in the Americas region. Knight ... senior vice president, chief communications officer. In this ... leading corporate brand initiatives and reputation management to ... South America . She will ...
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... 5, 2011 SyncMedical LLC today announced ... – Brazilian National Health Surveillance Agency) has approved their ... in Brazil. SyncMedical,s Ethos Spine product line was developed ... treatment solutions to surgeons in the ever-growing, ever-changing field ...
... Jan. 5, 2011 Heska Corporation (Nasdaq: HSKA ... Conference hosted by Sidoti & Company, LLC on Monday, January ... 42nd Street (Park Avenue at Grand Central) in New York ... Eastern Time. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
Cached Medicine Technology:SyncMedical Receives ANVISA Regulatory Approval to Offer Spine and Internal Medicine Products in Brazil 2
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, ... hungry for their partner, to the point of starvation, that they ... has been taught to hundreds of men and women across the ... Ex review , Shane Michaels agrees this simple trick is genius ... a second chance at getting back together with their ex. ...
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... US Hair Restoration Founder, Dr. Parsa Mohebi, has recently ... Mohebi Hair Restoration. Since first opening in 2008, US ... and around the world, who traveled to one of its ... patients achieved the full benefits of a variety of hair ... Dr. Mohebi. They have come to understand how his ...
Breaking Medicine News(10 mins):Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... GAP, Pa., April 1, 2008 Core People ... Service Corporation,(CCSC) of Wexford, PA. CCSC provides options ... benefits for Pennsylvania chamber members through,its ChamberChoice portfolio., ... to offer a,broader level of employer services, including ...
... Awareness among Hispanic Community as Fewer ... Receiving Diagnosis and Support, CHICAGO, April 1, ... individuals living with autism, among the,vast array of services the national ... the last 20 years, Easter Seals has seen a dramatic increase ...
... rates to that from younger donors , , TUESDAY, April ... 75 should be allowed to donate corneas for transplant, says ... that tissue from donors aged 66 to 75 had the ... aged 12 to 65. , The research, coordinated by the ...
... the pharmaceutical industry currently underway will increase in the ... researcher at the National Institutes of Health (NIH) who ... development. , According to Christopher Austin, M.D., ... industry and academia welcome more cooperation in drug discovery ...
... CHICAGO, Ill. (April 1, 2008) Many patients ... percutaneous coronary intervention (PCI) are already taking 75mg ... Even so, an additional 600-mg reloading dose of ... risk of bleedingbut only in patients with acute ...
... 1, 2008 Senetek PLC (OTC,Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, ... has secured financing in an,amount up to $28 ... of men,s health treatments, including Invicorp(R)., Plethora ...
Cached Medicine News:Health News:Core People Partners to Expand Services 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Study Finds Older Corneas Suitable for Transplantation 2Health News:Business of drug development on verge of great change 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: